Melanoma

Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Background Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic …
Cite Doi ScienceDirect
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
Background Melanomas lacking mutations in BRAF, NRAS and NF1 are frequently referred to as “triple wild-type” (tWT) melanomas. They …
Cite Doi ScienceDirect
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Purpose Clinical trials demonstrated significantly improved recurrence-free survival (RFS) of melanoma patients receiving adjuvant …
Cite Doi ScienceDirect PubMed
Accuracy of a Smartphone-Based Artificial Intelligence Application for Classification of Melanomas, Melanocytic Nevi, and Seborrheic Keratoses
Current artificial intelligence algorithms can classify melanomas at a level equivalent to that of experienced dermatologists. The …
Cite Doi PDF PubMed
Characterisation and outcome of RAC1 mutated melanoma
Background Activating hot spot R29S mutations in RAC1, a small GTPase influencing several cellular processes including cell …
Cite Doi ScienceDirect PubMed